PRN® Omega-3 is the only formula clinically proven in Dry Eye patients that improves both signs and symptoms of Dry Eye.
PRN Physician Recommended Nutriceuticals® is the leading developer of specialty omega-3 products. Developed and endorsed by medical thought leaders, PRN® products are supported by clinical evidence and are unmatched in quality and purity.
Significant Improvement inTEAR OSMOLARITYReduction of 19.4 mOsm/ L
At the 6-week follow-up, a significant reduction from baseline was measured in tear film osmolarity in the omega-3 group (−16.8 ± 2.6 mOsm/L) versus control group (−9.0 ± 2.7 mOsm/L, P = 0.042), which further decreased from baseline at 12 weeks in the omega-3 group (−19.4 ± 2.7 mOsm/L) versus control group (−8.3 ± 2.8 mOsm/L, P = 0.004).
Significant Improvement inTEAR BREAK-UP TIME3.5 second increase
TBUT showed a significant improvement during the 12 weeks in the omega-3 group. At 6 weeks, there was a trend toward TBUT improvement in the omega-3 group, which was not statistically significant (P = 0.126), but the difference between the groups was significant at the 12-week visit (P = 0.002).
Significant Improvement inOSDI50% drop in score
Both groups had similar OSDI symptom scores at baseline. At 12 weeks, OSDI symptom scores in the omega-3 group dropped from 32.4 ± 19.2 to 15.5 ± 11.0 versus 27.1 ± 22.9 to 22.0 ± 19.3 in the control group (P = 0.002).
Bioavailability of EPA+DHA fromRE-ESTERIFIED TRIGLYCERIDESwas superior (124%) compared with natural fish oil
POTENCYNot all Omega-3s are created equal